Neoadjuvant nivolumab plus chemotherapy extends EFS in non-small cell lung cancer

Neoadjuvant nivolumab plus chemotherapy significantly improved EFS in stage IB to stage IIIA resectable non-small cell lung cancer, according to research presented at American Association for Cancer Research Annual Meeting.
Results of the randomized phase 3 CheckMate 816 trial, published simultaneously in The New England Journal of Medicine, also showed no new adverse events associated with the nivolumab (Opdivo, Bristol Myers Squibb) combination.
“Right now, this is the standard of care for all patients with resectable stage IB to stage IIIA NSCLC,” Nicolas Girard, MD, PhD,

Neoadjuvant nivolumab plus chemotherapy significantly improved EFS in stage IB to stage IIIA resectable non-small cell lung cancer, according to research presented at American Association for Cancer Research Annual Meeting.
Results of the randomized phase 3 CheckMate 816 trial, published simultaneously in The New England Journal of Medicine, also showed no new adverse events associated with the nivolumab (Opdivo, Bristol Myers Squibb) combination.
“Right now, this is the standard of care for all patients with resectable stage IB to stage IIIA NSCLC,” Nicolas Girard, MD, PhD,